Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
really!!! as i posted this's why i keep my shares, that pr is the near future of bhrt.
this is why i chose to stay in bhrt, and anncouncement of sales in place would be a great thing.
Bioheart, Inc. (OTCBB:BHRT) and Airspeed Equity LLC, a private investment, entrepreneurial capital management firm, today announced four major products - MyoStim Lab Culture Stimulator, Limb Blood Flow Stimulator, and Implantable Heart Pacemaker and the Biopace Biological Pacemaker.
Airspeed Equity has an exclusive licensing agreement for these products with Bioheart. Under the terms of the Agreement Bioheart will receive milestone based cash payments as well as royalty payments on all net sales. Sales are expected to commence this coming year for the MyoStim Lab Cell Culture Stimulator and MyoStim Limb Blood Flow Stimulator.
"We're excited about developing these four important and potentially life-saving products here in San Diego, the heart of the biotechnology and healthcare community," said Alan Remen, Founder and Managing Director of Airspeed Equity. "This project fits perfectly within our charter to help entrepreneurs, business owners, and major shareholders of companies design strategies for growth and innovation in new and emerging markets."
"The discovery that low voltage electrical stimulation of the heart can both regenerate damaged heart tissue and replace high voltage implantable defibrillators for arrhythmia fibrillation recovery may change the course of care for the more than 30 million patients suffering of heart failure worldwide," said Howard Leonhardt, Bioheart's co-founder and Chief Technology Officer.
the following is what keeps me from selling:
We own or hold licenses or hold sublicenses to an intellectual property portfolio consisting of approximately 19 patents and 19 patent applications in the United States, and approximately twelve patents and 57 patent applications in foreign countries, for use in the field of heart muscle regeneration. Our intellectual property strategy emphasizes method, product and device patents. We rely primarily on one U.S. patent for MyoCell, or the Primary MyoCell Patent, one U.S. patent for MyoCath, or the Primary MyoCath Patent and a number of patents for MyoCath II. We rely on three pending U.S. patent applications and corresponding foreign patent applications for MyoCell SDF-1 and three U.S. patents for BioPace. For most of our other product candidates, we rely on one primary patent, multiple patents in combination and/or proprietary processes. The following provides a description of our key patents and pending applications and is not intended to represent an assessment of claims, limitations or scope.
i wonder if some warrants are being exercised, could be pr firm cashing in?
the interest in this stock is certainly understandable, i think we'll see alot more buying tomorrow and so on. if your going to play the pinks this's one of those stocks you need, i wouldn't call this a wild card. looking forward to some positive news in the near future, after all they do have alot going on.
bhrt having heavier than usual trading activity, i wonder what has triggered the sells? whatever the case may be i'd say news will be comming shortly.
heavy volume today, 100 shares. was that a sell or a buy? i hope u were expecting better news than that.
i think you missed my meaning, the treatment could be saving thousands of lives. in the mean time we wait for the fda to approve the treatment.
i still have fingers crossed on buy out opportunity. if nothing else open up shop in a 3rd world country and let people take advantage of this wonderfull tool, when it comes to one more breath of fresh air how do u put a dollar value to it.
was that news on negs or tsrr?
thats not to far away, were just about thru this week. until next week.
decent volume today, also picked up some more. when do you think bioheart will be making more announcements?
thankyou, i'll check it out.
does negs affect tsrr in any way? is tsrr still a womans football league? tia
does the inverted candle indicate downward pressure?
i'll have to see how this saga plays out at a later time, have some work that needs my attention. imagine that some of us actually work for a living, unlike some gold brickers. later
i agree 100%, do you think he cares if it hurts 500 investors on the retail end. you know the answer to that, carpet bagger with no wares.
dd, thanks for that info makes me feel better about my assumptions, as usual i'm zeroed in..boom
my my, seems rash has a history. looks like his latest target is vakser, i don't see a settlement going in rash's direction. as i said before, he needs to get a job, get a little dirt on him. then on the other hand maybe he's better suited as a greeter at some well known store chain.
newmanater i have a shell company that was in default for a year, they paid the state of nevada their money and its no longer in default. i don't know why these companies choose to agravate us with these things but lots of them do, default is not the end of the world. note: contrary to some post here, default does not mean expulsion. it just means they haven't paid their yearly fees, with all the reorganizing that seems to be happening with arts, pbhg, tsrr and others they may be holding off to see what the officers lists will be with the state of nevada. why pay twice or three times, i'm grasping at straws but i would think it all comes down to getting the annual list of officers and addresses correct the first time.
one other thing, if you (rash) are reading this go get yourself a job. everyone that gets fired or layed off always feels slighted and they are always the victim. i don't know you and i don't know vakser, but i do know about corporations. when i want to get rid of someone and as long as it's not discrimination i can dust people all day long. i don't even have to have a reason, but common decency comes into play if i so desire.
how long did you work for arts and what did you do for arts. was your efforts really worth 800k, i doubt it. if you had such and impact on arts you'd still be there and arts probably wouldn't be .0001
i wonder if the preciding judge will ask what makes you worth 800k, thats alot money. the judge himself is probably in the 130k range, he'll have a feel for man hours and dollar worth. i think i'm worth 800k a year, i wonder who i can sue.
will a continuance be granted to rash? the burden of proof is on rash, if vakser goes to court today with a attorney that continuance will be up for grabs. a good attorney will cite rash for vindictivness and is merely stalling while going on a fishing expedition. if a continuance is denied rash and his attorney will have to belly up to the bar with their evidence. i'm not a big fan of corporate greed, i'm also not a big fan of someone trying to get 800k which would hurt everyone involved with these companies. does rash have a signed contract stating all the compensations he's seeking? if he doesn't i'd say he's wasted his money!
on a side note..i have a feeling one of the posters on this board is rash, his accusations have been gleened from this and arts forum.
no filings, no news, this ceo is such a sleeze! at this rate shares should be in the .000 range before long. everything this guy touches goes into hibernation, the pps just keep on slipping.
thank you for the vote of confidence.
i just reread the filing, what a joke. this rash and the attorney he has must of been at the bottom of the class. sueing for wages is one thing, all the other items he's grasping at are of a differnt matter. those matters are what the prosecuting attorney in dallas charge, not to mention a grand jury. sorry if i seem un excited about all this, its going to get thrown out the way it is written. a first year law student could of done better.
the silk purse and sows ear, brilliant! and the best part, rash continues to suffer. join the crowd, get a friggin job.
i say off with all there heads, rash included.
interesting law suit, personally i think we have a case of the pot calling the kettle black. lets say ed and family were actually doing as accused, my guess steven rash was in full acknoledgement. so if he wins he's stolen from arts investors twice!
has the sec brought charges, as far as i can research on the sec site the answer is no. the guy just got thru filing, regardless of the duration. my guess the sec scrutinized it pretty close.
has the attorney general from the state of nevada filed charges, as far as i can research the answer is no. all this bs about not being current with the state of nevada, has no bearing and is easily rectified with a few hundred bucks.
rash is trying to get a payday at arts investors expense. do u think mr. rash cares how this turns out for those holding shares in arts and those that may/ possibly be getting divies from pbhg. i'm not a big fan of ed and alot of the implications implied ,i think steve RASH MAY BE A BIG SCAB. the money he's attempting to get should be in your pockets not rash's.
and the big discovery of transfering assets, really! i think rash really sucked at his job and angie or ed probably dumped him, so this seems more in the disgruntled employee realm. he should of called the nlrb instead of getting a lawer, and the way this law suit has been stacking up i think he's pulling all of his steam from this board.
this whole matter pizzes me off, these three companies may of started to move in the near future. this giant rash has got me scratching, as far as i'm concerned he can take a hike.
we sure have met resistance, if we could lose the sellers this would be moving up nicely, pr firm put out news this morning so they would be selling into any potential run. hope fully the seller move on and the buyer move in, it would be nice for this to move up to its potential high.
ONE OTHER THING, if i was a rich man and had serious heart problems i would engage bhrt to meet me in a country that would let them myoblast my heart, hummm, that is a big possibility.
NEWS!!
Press Release Source: Bioheart Inc. On Tuesday October 18, 2011, 5:00 am
SUNRISE, Fla., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT.OB - News) was among top scientists and physicians presenting cutting edge data at the Controversies and Advances in the Treatment of Cardiovascular Disease Conference in Los Angeles last week. A summary of data on the use of adult muscle stem cells (immature myoblasts) to treat advanced heart failure was presented by Howard Leonhardt, Bioheart's co-founder and Chief Technology Officer. Bioheart is one of the only companies in phase II/III trials using stem cells. More than 400 patients have been treated with muscle stem cells and the following results have been published in peer reviewed journal articles:
84% of MyoCell treated patients have improved in at least one parameter while only 16% have worsened.
33% of MyoCell treated patients have improved by two heart failure classes.
MyoCell treated patients improved 91.7 meters in exercise capacity while placebo patients declined 4 meters.
MyoCell is the only cell composition that has demonstrated an ability to grow new contractile muscle in heart scar tissue.
In addition to the above summary from clinical trials completed by Bioheart, Mr. Leonhardt presented published pre-clinical data demonstrating repeat percutaneous injections of myoblasts can bring even greater improvement to heart failure patients.
Click here to read more about repeat injections using myoblasts:
http://www.ncbi.nlm.nih.gov/pubmed/19700775
Bioheart's CEO and President, Mike Tomas said, "Our clinical programs are among the most advanced in the cell therapy sector and the clinical results over the past 10 years have demonstrated the safety and efficacy of myoblast therapies. We are committed to continuing these programs and bringing these therapies to commercialization."
About Bioheart, Inc.
Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Our leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit http://www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.
i still think the sell off is the pr firms, there like leeches. as this shoots thru the roof i sure hope they choke on it.
thats alot to take in, if i had heart problems i'd want to find this company. talk about cutting edge technology, i wonder how this will work with cancer treatments in the future, this could be one huge step for medicine. if your wondering why this stock is rising read my last post, 8 cents for this stock..rediculous.
bhrt
We own or hold licenses or hold sublicenses to an intellectual property portfolio consisting of approximately 19 patents and 19 patent applications in the United States, and approximately twelve patents and 57 patent applications in foreign countries, for use in the field of heart muscle regeneration. Our intellectual property strategy emphasizes method, product and device patents. We rely primarily on one U.S. patent for MyoCell, or the Primary MyoCell Patent, one U.S. patent for MyoCath, or the Primary MyoCath Patent and a number of patents for MyoCath II. We rely on three pending U.S. patent applications and corresponding foreign patent applications for MyoCell SDF-1 and three U.S. patents for BioPace. For most of our other product candidates, we rely on one primary patent, multiple patents in combination and/or proprietary processes. The following provides a description of our key patents and pending applications and is not intended to represent an assessment of claims, limitations or scope.
Home
About Us
Products
Clinical Programs
Videos
Careers
Investor Relations
In The News
Events
Centers of Excellence
Contact
MyoCell
MyoCell SDF-1
MyoCath
Product Candidates
Myocell®
The human heart does not have cells that naturally repair or replace damaged heart muscle. Accordingly, the human body cannot, without medical assistance, repopulate regions of scar tissue within the heart with functioning muscle. MyoCell is a clinical therapy designed to improve cardiac function by populating regions of scar tissue within a patient's heart with muscle stem cells (myoblasts) derived from a biopsy of a patient's thigh muscle. Myoblasts are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate muscle. When injected into scar tissue within the heart wall, myoblasts have been shown to be capable of engrafting in the damaged tissue and differentiating into mature muscle cells. In a number of clinical and animal studies, the engrafted muscle cells have been shown to express various proteins that are important components of contractile function. The use of myoblasts obtained from a patient's own body to treat chronic heart damage has several distinct advantages to the use of other cell types including but not limited to the following:
•
Since the myoblasts are patient-derived it reduces the risk of tissue rejection;
•
Myoblasts are committed to forming muscle and will not differentiate into other cell types in the heart;
•
Myoblasts do not over-proliferate so there is no risk of forming tumors in the heart;
•
Myoblasts better tolerate the low-oxygen environment of scar tissue (therefore surviving better in the heart) as it is not unlike the environment in which myoblasts naturally reside in the thigh muscle;
•
Myoblasts are the only progenitor cells in the human body that normally develop a contractile apparatus, which makes them more likely to restore contractile function in the damaged fibrous regions of the heart;
•
Myoblasts normal function is to regenerate muscle after injury or trauma;
•
Myoblasts are easily expandable in culture allowing for high yields to be obtained in order to replace the many cells that have been lost in the damaged heart.
Our preclinical and clinical research to date suggests that MyoCell may improve the contractile function of the heart. Some theories as to why contractile function improves include:
•
The engrafted myoblasts can contract in unison with the other muscle in the heart by stretching;
•
The myoblasts acquire certain characteristics of the heart muscle cells or fuse with them;
•
The injected myoblasts release various proteins that indirectly result in limiting scar tissue formation;
•
The myoblasts may limit the remodeling (or enlargement) of the heart.
As part of the MyoCell therapy, a general surgeon removes approximately five to ten grams of thigh muscle tissue from the patient utilizing local anesthesia, typically on an outpatient basis. The muscle tissue is then shipped to Bioheart’s cell culturing site. At the cell culturing site, our proprietary techniques are used to isolate and remove myoblasts from the muscle tissue. We typically produce enough cells to treat a patient within approximately 14 to 21 days of his or her biopsy. Such production time is expected to continue to decrease as we continue to refine our cell culturing processes. After the cells are subjected to a variety of tests, the cultured cells are packaged in injectate media and shipped to the interventional cardiologist. Within four days of packaging, the cultured myoblasts are injected via a needle injection catheter directly into the scar tissue of the patient's heart. The injection procedure takes on average about one hour and can be performed with or without general anesthesia. Following treatment, patients generally remain in the hospital for approximately 48-72 hours for monitoring. The MyoCell injection procedure is minimally invasive which presents less risk and considerably less trauma to a patient than conventional (open) heart surgery. Patients are able to walk immediately following the injection process and require significantly less time in the hospital compared with surgically treated patients.
We use a number of proprietary processes to create therapeutic quantities of myoblasts from a patient's thigh muscle biopsy. We have developed and/or licensed what we believe are proprietary or patented techniques to:
•
Transport muscle tissue and cultured cells;
•
Disassociate muscle tissue with manual and chemical processes;
•
Separate myoblasts from other non-useful cells;
•
Identify a cell population with the propensity to engraft, proliferate and adapt to the cardiac environment; and
•
Maintain and test the cell quality and purity.
Assuming we secure regulatory approval of MyoCell for the treatment of all NYHA Class II and NYHA Class III patients, we believe MyoCell will provide a treatment alternative for the millions of these patients in the United States and Europe who either do not qualify for or do not have access to a heart transplant. Furthermore, we anticipate that the time incurred and cost of identifying patients qualified to receive MyoCell as well as the cost of MyoCell, including any ICD, drug and bi-ventricular pacer therapies that are simultaneously prescribed, if any, will be less expensive than the current cost of a heart transplant. Moreover, MyoCell is less invasive than a heart transplant and is not subject to the tissue rejection and immune system suppression issues associated with heart transplants.
We believe there is still a large population of patients exhibiting symptoms consistent with NYHA Class II and NYHA Class III heart failure that is seeking an effective or more effective therapy for chronic heart damage than ICDs, bi-ventricular pacers and drug therapies. We hope to demonstrate that MyoCell is complementary to various therapies including ICDs, bi-ventricular pacers and pharmaceuticals.
Candidate
Proposed Use or Indication
Status/Phase
MyoCell®
Autologous muscle stem cell therapy for the treatment of severe heart damage in heart failure patients
Phase I, Phase I/II and Phase II trials completed. Phase II/III underway
Comments: Prior MyoCell clinical trials include MYOHEART (20-patient U.S. Phase I dose-finding study) and SEISMIC (40-patient European Phase II-a safety study). MYOHEART and SEISMIC demonstrated no unexpected safety issues in this very sick patient population and suggested trends toward improvement in efficacy parameters.
Copyright © Bioheart, Inc. 2009. All Rights Reserved.
13794 NW 4th Street, Suite 212 | Sunrise, Florida 33325 | Telephone: (954)-835-1500 | Fax: (954)-845-9976 | bioheart@bioheartinc.com
you'll have to go to their home page.
mr.ed,
when will the grey come off, give us a firm date.
when will arts filing take effect, all i read about is working on it. my suggestion to you is find another auditor that will divote his complete attention to this and get it done, enough delays already.
do not launch anything until you have your act together, i would laugh my azz off if you came to me to invest after looking at the affairs of these companies.
where are these so called investors that have so much faith it your plan, why aren't they buying over the counter? are they getting shares at a fraction of the cost? if so that eventually translates into massive dilution. these sales pitches your giving is like trying to sell a new car in primar and minus a motor.
a dollar would be a fair assessment, i would like to see it happen just so the pr firms could say damn. pr firms are one of the most damaging companies to the pps, they don't have any restrictions.
getting past pr firms, bhrt has alot of inovative ideas. research and devolopment departments have got to be scammbling to get in the game.
no action for arts, pbhg and or tsrr, no action until this mess is cleared up. grey, caveat and the steady decline of pbhg. i'm not being a azz i'm just stating the facts, most investors from the over the counter have been burned so many times that they do a fair amount of dd. ed, you can pump your products until your blue in the face and nothing is going to happen until arts is cleaned up, tsrr is off of the greys and pbhg is stabilized. i don't think there is any help with pbhg until arts and tsrr are right.
the reason this meets so much resistance is the pr firms that bhrt pays in stock are selling their shares. the pr firms are slime balls, they always have been and alway will be!
10 t0 15 times current pps, most studies that go thru all 3 phases cost a billion plus. bhrt has about 100 million invested. the reason we haven't spent 1 billion is alot of the studies were done in 3rd world countries and universities worked with bhrt pro bono. so based on our investment of 10% of the normal cost and 51 patents along with marketable products, 10 to 15 times current pps is reasonable.
waiting for that buy out announcment, i think would be canidates are already licking their chops. i feel theres more than one company looking at bhrt, probably researching the possibilty of going around bhrt patents, when they find out they can't they'll be a buy out. also the marvel 2 and 3 phase study thats approved by our gov., has gotten peoples attention. 99% sure a buy out is in our near future.